Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032097 | 0.99 | NAMPT (0.36) | NAMPTTSHR | |
| SCHEMBL22032109 | 0.95 | NAMPT (0.36) | NAMPTTSHRMEN1KMT2ADPP4 | |
| SCHEMBL22032104 | 0.82 | — | — | |
| SCHEMBL22032122 | 0.76 | NR1H2 (0.33) | — | |
| SCHEMBL22032085 | 0.75 | HTR2A (0.30) | — | |
| SCHEMBL22032113 | 0.74 | — | — | |
| SCHEMBL22032088 | 0.72 | NAMPT (0.36) | NAMPTTSHR | |
| SCHEMBL22032071 | 0.69 | CHRM1 (0.48) | MEN1KMT2A | |
| SCHEMBL24106273 | 0.68 | CHRM1 (0.39) | TSHRKMT2A | |
| SCHEMBL22032111 | 0.68 | CHRM1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | claimed |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-12-16 | — | — | US | claimed |
| EP-3891140-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2021-10-13 | — | — | EP | claimed |
| WO-2020115505-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | claimed |
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| EP-3891140-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115505-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | NAMPT 2529/4885TSHR 81/4885MEN1 713/4885 |
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | NAMPT 2529/4885TSHR 81/4885MEN1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.